Table 4 Anti-relapse efficacy of tafenoquine in various regimens and primaquine in human cases compared to chloroquine in Thailand (from Walsh et al 1999; 2004).
Drug | Dose | Total Dose | #Subjects | #Relapses | Efficacy (% +/- 95% CI) | Comment on Relapse |
|---|---|---|---|---|---|---|
Tafenoquine | 500 mg | 500 | 9 | 1 | 87 (-37-100) | Relapse delayed |
Tafenoquine | 600 mg | 600 | 18 | 1 | 96 (67-99) | Vomiting |
Tafenoquine | 600 mg × 3 | 1800 | 19 | 0 | 100 (78-100) | |
Tafenoquine | 300 mg × 7 | 2100 | 19 | 0 | 100 (78-100) | |
Tafenoquine | 300 mg × 7 | 2100 | 15 | 0 | 100 (24-100) | |
Tafenoquine | 500 mg × 3, repeated | 3000 | 11 | 1 | 87 (-34-100) | Relapse delayed |
Primaquine | 15 mg × 14 | 12 | 3 | 80 (15-97) |